viacyte
-
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout
Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.
-
CRISPR Therapeutics, ViaCyte partner on diabetes therapies
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, BioPharma
Gore joins ViaCyte’s quest for a functional type 1 diabetes cure
Through a new partnership with the maker of GORE-TEX, San Diego’s ViaCyte is looking to finetune its PEC-Encap combination device that could one day offer a functional cure for type 1 diabetes.
-
Devices & Diagnostics, Pharma, Startups
Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership
San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced […]
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
